These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34784005)

  • 1. Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis.
    Gourdy P; Bonadonna RC; Freemantle N; Mauricio D; Müller-Wieland D; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M
    Diabetes Ther; 2022 Jan; 13(1):57-73. PubMed ID: 34784005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis.
    Mauricio D; Gourdy P; Bonadonna RC; Freemantle N; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M; Müller-Wieland D
    Diabetes Ther; 2021 Apr; 12(4):1159-1174. PubMed ID: 33751403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis.
    Bonadonna RC; Mauricio D; Müller-Wieland D; Freemantle N; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M; Gourdy P
    Diabetes Ther; 2021 Apr; 12(4):1073-1097. PubMed ID: 33650085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database.
    Müller-Wieland D; Freemantle N; Bonadonna RC; Mauquoi C; Bigot G; Bonnemaire M; Gourdy P; Mauricio D
    Diabetes Ther; 2023 Feb; 14(2):401-413. PubMed ID: 36596946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study.
    Sethi B; Al-Rubeaan K; Unubol M; Mabunay MA; Berthou B; Pilorget V; Vethakkan SR; Frechtel G
    Diabetes Ther; 2022 Jul; 13(7):1395-1408. PubMed ID: 35713873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
    Haluzík M; Cheng A; Müller-Wieland D; Westerbacka J; Bosnyak Z; Lauand F; Melas-Melt L; Karalliedde J; Rosenstock J; Bolli GB
    Diabetes Obes Metab; 2020 Aug; 22(8):1369-1377. PubMed ID: 32243043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
    Haluzík M; Seufert J; Guja C; Bonnemaire M; Bigot G; Tournay M; Kis JT; Freemantle N
    Diabetes Ther; 2023 Apr; 14(4):639-652. PubMed ID: 36787044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
    Landgraf W; Owens DR; Frier BM; Zhang M; Bolli GB
    Diabetes Obes Metab; 2020 Mar; 22(3):315-323. PubMed ID: 31608548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.
    Giaccari A; Bonadonna RC; Buzzetti R; Perseghin G; Cucinotta D; Fanelli C; Avogaro A; Aimaretti G; Larosa M; Pagano V; Bolli GB
    Acta Diabetol; 2021 Jun; 58(6):789-796. PubMed ID: 33586058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study.
    Kamenov Z; Pehlivanova V; Kuneva T; Kirilov K; Bobeva R; Stoykova J; Mihalevska S
    Diabetes Ther; 2021 Mar; 12(3):913-930. PubMed ID: 33604804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.
    Galstyan GR; Tirosh A; Vargas-Uricoechea H; Mabunay MA; Coudert M; Naqvi M; Pilorget V; Khan N
    Diabetes Ther; 2022 Jun; 13(6):1187-1202. PubMed ID: 35532858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
    Kovatchev B; Meng Z; Cali AMG; Perfetti R; Breton MD
    Diabetes Ther; 2020 Jun; 11(6):1293-1302. PubMed ID: 32304086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.